References

Multiple myeloma

10.1016/s0140-6736(21)00135-5 · 2021 · External reference

Multiple myeloma current treatment algorithms

10.1038/s41408-020-00359-2 · 2020 · External reference

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

10.1038/s41408-020-0273-x · 2020 · External reference

Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum guideline

10.1111/bjh.17410 · 2021 · External reference

Future directions in maintenance therapy in multiple myeloma

2021 · External reference

Lenalidomide after stem-cell transplantation for multiple myeloma

10.1056/nejmoa1114083 · 2012 · External reference

Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

10.3324/haematol.2020.247130 · 2020 · External reference

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma

10.1056/nejmoa1114138 · 2012 · External reference

Autologous transplantation and maintenance therapy in multiple myeloma

10.1056/nejmoa1402888 · 2014 · External reference

Continuous lenalidomide treatment for newly diagnosed multiple myeloma

10.1056/nejmoa1112704 · 2012 · External reference

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(18)30687-9 · 2019 · External reference

Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline

10.1200/jco.18.02096 · 2019 · External reference

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial

10.1200/jco.2011.39.6820 · 2012 · External reference

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

10.1016/s0140-6736(18)33003-4 · 2019 · External reference

Ixazomib vs placebo as post-induction maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients (PTS) not undergoing autologous stem cell transplant (ASCT): phase 3 tourmaline-mm4 trial

10.1200/jco.20.02060 · 2020 · External reference

10.1016/s1470-2045(21)00428-9

10.1016/s1470-2045(21)00428-9 · 2021 · External reference

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

10.1016/s1470-2045(24)00282-1 · 2024 · External reference

Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis

10.1001/jamaoncol.2018.2961 · 2018 · External reference

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations

10.7326/m14-2385 · 2015 · External reference

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

10.1136/bmj.39489.470347.ad · 2008 · External reference

10.3324/haematol.2019.240374

10.3324/haematol.2019.240374 · 2020 · External reference

Long-term efficacy of maintenance therapy for multiple myeloma: a quantitative synthesis of 22 randomized controlled trials

2018 · External reference

A systematic review and network meta-analysis of maintenance treatment for patients with newly diagnosed multiple myeloma post-autologous stem cell transplant

2017 · External reference

Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis

10.1080/16078454.2021.2009648 · 2021 · External reference

Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: a systematic review and meta-analysis

10.1111/ejh.13506 · 2021 · External reference

10.1182/blood-2019-130644

10.1182/blood-2019-130644 · 2019 · External reference

Safety and efficacy of combination maintenance therapy with ixazomib and lenalidomide in patients with posttransplant myeloma

10.1158/1078-0432.ccr-21-3420 · 2022 · External reference

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

10.1182/blood.2022019531 · 2023 · External reference

10.1016/s1470-2045(21)00535-0

10.1016/s1470-2045(21)00535-0 · 2021 · External reference

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

10.1016/s1470-2045(22)00738-0 · 2023 · External reference

10.1016/s1470-2045(20)30452-6

10.1016/s1470-2045(20)30452-6 · 2020 · External reference

Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN

10.1182/blood.2020005288 · 2020 · External reference

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

10.1056/nejmoa2312054 · 2024 · External reference

Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in alcyone

10.1182/blood-2019-123401 · 2019 · External reference

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

10.1056/nejmoa2400712 · 2024 · External reference

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

10.1038/s41591-024-03050-2 · 2024 · External reference

Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients

10.1182/blood-2023-177546 · 2023 · External reference

10.1016/s2352-3026(22)00263-0

10.1016/s2352-3026(22)00263-0 · 2022 · External reference

Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis

10.1200/jco.2017.72.6679 · 2017 · External reference

Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients

10.1182/blood.2022018339 · 2022 · External reference

Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis

2020 · External reference